Affiliations: [a] Maccabi Healthcare Services, Tel Aviv, Israel | [b] The Department of Family Medicine, The Sackler Faculty of Medicine. University of Tel Aviv, Tel Aviv, Israel | [c] Memory clinic, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel | [d] Department of Preventive Medicine, Icahn School of Medicine at Mount Sinai, New York, USA | [e] Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, USA | [f] The Josef Sagol Neuroscience Center, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel
Correspondence:
[*]
Correspondence to: Professor Anthony David Heymann, Maccabi Healthcare Services, 27 Hamered Street, Tel Aviv 68125, Israel. Tel.: +972 508800130; tonyheymann@gmail.com
Abstract: The pleiotropic contribution of statins on cognition is uncertain. From 840 patients in the cohort from the Israel Diabetes and Cognitive Decline Study, we identified 61 non-statin users and compared them with 45 patients who had used statins at least 90% of the time. Analysis of covariance was performed to compare mean cognitive z-scores between statin users and non-users while adjusting for socio-demographic, diabetes-related, and cardiovascular covariates which included change in cholesterol by year. Overall cognition, memory, and executive function was found to be significantly better in statin users (p < 0.0008). This suggests a positive effect of statins on cognitive function of type 2 diabetes patients that is independent of cholesterol levels.
Keywords: All cognitive disorders/dementia, Alzheimer’s disease, case control studies, diabetes
